Financial chart
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Lynas Rare Earths Ltd (ASX:LYC) saw its net profit after tax (NPAT) in the first quarter of the 2025 fiscal year plunge by 85%, to $5.9 million (from $39.5M in 1H24), despite an 8% rise in revenue, which came in at $254.3 million.

The company said its earnings (EBITA: earnings before interest, taxes, depreciation and amortization) had also been lower, at $38.1M compared to $62.6M in the prior corresponding period.

CEO and managing director Amanda Lacaze said the dipping numbers were largely due to lower pricing.

“In the December half of the 2025 financial year, Lynas increased NdPr production, sales volume and revenue versus the prior corresponding period,” she explained.

“The reduced profit recorded for the period reflected low market prices.

“Compared to the prior corresponding period, there was a 22% increase in NdPr production volume to 2,969t. Sales revenue increased to $254.3m due to the increased NdPr sales volume.

“This was achieved despite the average China domestic price of NdPr (VAT excluded) decreasing from US$56/kg in December 2023 to US$49/kg in December 2024. NdPr family sales volumes increased by 23% during the period.”

Lynas has been trading at $6.97.

Join the discussion: See what HotCopper users are saying about Lynas Rare Earths and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

lyc by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX 200 rallies as risk appetite returns, but business confidence weakens

The Australian sharemarket finished firmly higher today with the S&P/ASX 200 adding 106.50 points, or 1.18%, to close at 9,136.20.

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…

Nanoveu’s EMASS signs DigiKey as Global Distributor for ECS-DoT-22

Nanoveu's wholly-owned subsidiary EMASS has signed DigiKey as its global distributor for ECS-DoT-22 system.
The Market Online Video

Wealth Within: Wall Street Tech Sinks While ASX Tech Soars

Wall Street’s technology stocks have been hammered, with the Nasdaq plunging 5.5 per cent in a single session and Nvidia falling more tha…